AMIODARONE TABLET

Land: Canada

Språk: engelsk

Kilde: Health Canada

Aktiv ingrediens:

AMIODARONE HYDROCHLORIDE

Tilgjengelig fra:

SIVEM PHARMACEUTICALS ULC

ATC-kode:

C01BD01

INN (International Name):

AMIODARONE

Dosering :

200MG

Legemiddelform:

TABLET

Sammensetning:

AMIODARONE HYDROCHLORIDE 200MG

Administreringsrute:

ORAL

Enheter i pakken:

100

Resept typen:

Prescription

Terapeutisk område:

CLASS III ANTIARRYTHMICS

Produkt oppsummering:

Active ingredient group (AIG) number: 0118593001; AHFS:

Autorisasjon status:

APPROVED

Autorisasjon dato:

2012-05-31

Preparatomtale

_ _
_Amiodarone _
_Page 1 of 65_
_ _
_ _
PRODUCT MONOGRPAH
PR
AMIODARONE
Amiodarone Hydrochloride tablets, BP
200 mg
Antiarrhythmic Agent
SIVEM PHARMACEUTICALS ULC
Date of Revision:
4705 Dobrin Street
October 27, 2016
St. Laurent, Quebec
H4R 2P7
www.sivem.ca
Control number: 198891
_ _
_Amiodarone _
_Page 2 of 65_
_ _
_ _
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
........................................................................................
3
SUMMARY
PRODUCT
INFORMATION
..............................................................................................................
3
INDICATIONS
AND
CLINICAL
USE
....................................................................................................................
3
CONTRAINDICATIONS
.........................................................................................................................................
4
WARNINGS
AND
PRECAUTIONS
........................................................................................................................
4
ADVERSE
REACTIONS
.......................................................................................................................................
19
DRUG
INTERACTIONS........................................................................................................................................
23
DOSAGE
AND
ADMINISTRATION
....................................................................................................................
28
OVERDOSAGE
......................................................................................................................................................
30
ACTION
AND
CLINICAL
PHARMACOLOGY
...................................................................................................
31
STORAGE
AND
STABILITY
................................................................................................................................
34
SPECIAL
HANDLING
INSTRUCTIONS
....................................